Verve Therapeutics Inc [NASDAQ: VERV] closed the trading session at $10.95 on 2025-07-17. The day’s price range saw the stock hit a low of $10.925, while the highest price level was $11.05.
The stocks have a year to date performance of 52.93 percent and weekly performance of -0.99 percent. The stock has been moved at 108.57 percent over the last six months. The stock has performed 74.64 percent around the most recent 30 days and changed 120.32 percent over the most recent 3-months.
If compared to the average trading volume of 4.58M shares, VERV reached to a volume of 5598194 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Verve Therapeutics Inc [VERV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VERV shares is $12.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VERV stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Verve Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on April 15, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on April 08, 2024, representing the official price target for Verve Therapeutics Inc stock. Previously, the target price had yet another raise to $29, while Canaccord Genuity analysts kept a Buy rating on VERV stock.
The Price to Book ratio for the last quarter was 2.05, with the Price to Cash per share for the same quarter was set at 5.58.
VERV stock trade performance evaluation
Verve Therapeutics Inc [VERV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.99. With this latest performance, VERV shares gained by 74.64% in over the last four-week period, additionally plugging by 108.57% over the last 6 months – not to mention a rise of 94.15% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VERV stock in for the last two-week period is set at 74.78, with the RSI for the last a single of trading hit 0.19, and the three-weeks RSI is set at 0.34 for Verve Therapeutics Inc [VERV]. The present Moving Average for the last 50 days of trading for this stock 7.54, while it was recorded at 11.01 for the last single week of trading, and 6.30 for the last 200 days.
Verve Therapeutics Inc [VERV]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Verve Therapeutics Inc [VERV] shares currently have an operating margin of -349.68% and a Gross Margin at 88.53%. Verve Therapeutics Inc’s Net Margin is presently recorded at -303.64%.
Verve Therapeutics Inc (VERV) Capital Structure & Debt Analysis
According to recent financial data for Verve Therapeutics Inc. ( VERV), the Return on Equity (ROE) stands at -34.26%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -26.89%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Verve Therapeutics Inc’s Return on Invested Capital (ROIC) is -34.05%, showcasing its effectiveness in deploying capital for earnings.
Verve Therapeutics Inc (VERV) Efficiency & Liquidity Metrics
Based on Verve Therapeutics Inc’s (VERV) latest financial statements, the Debt-to-Equity Ratio is 0.14%, indicating its reliance on debt financing relative to shareholder equity.
Verve Therapeutics Inc (VERV) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Verve Therapeutics Inc. (VERV) effectively leverages its workforce, generating an average of -$660620.44 per employee. The company’s liquidity position is robust, with a Current Ratio of 9.84% and a Quick Ratio of 9.84%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Verve Therapeutics Inc [VERV] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VERV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Verve Therapeutics Inc go to -0.31%.
Verve Therapeutics Inc [VERV]: Institutional Ownership
There are presently around $94.79%, or 99.89% of VERV stock, in the hands of institutional investors. The top three institutional holders of VERV stocks are: ALPHABET INC. with ownership of 12.35 million shares, which is approximately 14.6618%. BLACKROCK INC., holding 6.62 million shares of the stock with an approximate value of $$32.31 million in VERV stocks shares; and BLACKROCK INC., currently with $$25.69 million in VERV stock with ownership which is approximately 6.2492%.
